logo-loader

Pharmaxis seeing a great deal of interest from potential LOXL2 program partners

Published: 07:10 12 Feb 2018 AEDT

Gary Phillips, chief executive of Pharmaxis Ltd (ASX:PXS) tells Proactive one of the key events for the company this year will be the mid‐year read out from the phase 1 studies that are underway on the two lead candidates from their anti fibrotic LOXL2 program.

''I've spent the last 12-18 months talking to potential partners'', Phillips says.

''We're looking for a company active in either NASH or IPF which is looking for an anti-fibrotic to add to their pipeline''.

''We've got about 10 companies which are seriously interested in the program we've been running … many of them are already under confidentiality agreements and some of them testing our compound in their laboratories so I can see a great deal of interest in this particular program''.

Syntara to start Phase 2 study targeting MDS

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of...

on 14/2/24